Enoxaparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002
Effectiveness of anticoagulation with unfractionated heparin for acute pulmonary embolism Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021
Comparison of low-molecular-weight-heparin and unfractionated heparin for acute PTE Source: Eur Respir J 2005; 26: Suppl. 49, 699s Year: 2005
Randomized trial of low-molecular-weight heparin compared with unfractionated heparin for acute pulmonary embolism Source: Eur Respir J 2001; 18: Suppl. 33, 382s Year: 2001
Comparison between the administration of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the treatment of pulmonary embolism Source: Annual Congress 2007 - Venous thromboembolic disease Year: 2007
Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer Source: International Congress 2018 – Diagnosis, prognostication and treatment of pulmonary embolism Year: 2018
One hour alteplase infusion plus low molecular weight heparin versus heparin alone in pulmonary embolism Source: Annual Congress 2003 - Pulmonary hypertension Year: 2003
Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin. Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019
Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020
Effectiveness of thrombolytic therapy in pulmonary thromboembolism Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007
The treatment of sub massive pulmonary embolism: Thrombolytic or heparin? Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012
The changing of D-dimer in the thrombolytic process of pulmonary thromboembolism Source: Eur Respir J 2006; 28: Suppl. 50, 401s Year: 2006
Thrombolytic therapy in massive pulmonary thromboembolism Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002
Complications of anticoagulant therapy in patients with pulmonary thromboembolism Source: Eur Respir J 2007; 30: Suppl. 51, 604s Year: 2007
Fixed or weight-adjusted dosis of enoxaparin as prophylaxis for venous thromboembolism in acutelly ill medical patients Source: Eur Respir J 2004; 24: Suppl. 48, 273s Year: 2004
Efficiency of r-TPA therapy in major venous thromboembolism Source: Eur Respir J 2007; 30: Suppl. 51, 83s Year: 2007
Thrombolytic therapy in cases with massive pulmonary thromboembolism Source: Eur Respir J 2005; 26: Suppl. 49, 521s Year: 2005
Efficacy of thrombolytic agents in the treatment of pulmonary embolism Source: Eur Respir J 2005; 26: 864-874 Year: 2005
Pulmonary embolism and pregnancy Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=177 Year: 2004
Fibrinolysis with tenecteplase in the management of massive pulmonary embolism Source: Eur Respir J 2004; 24: Suppl. 48, 559s Year: 2004